02206

95.0004.33%

IPO Tracker | Neautus's HK$329 million offering: the numbers behind China's second-largest TCM decoction pieces supplier

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Neautus (2206.HK) opened subscription on 30 October, running through 6 November, with an offer price range of HK$40.20 to HK$50.55 per share. At the top of the range, the company would raise a maximum of approximately HK$329 million. Based on the mid-point of the price range, net proceeds would be around HK$230 million, implying a market capitalisation of roughly HK$3.3 billion. That scale places this offering among the smaller listings on the Hong Kong market, meaning pricing will rely heavily on the syndicate's book-building capabilities.

The global offering comprises 6.5173 million H shares, with 10% allocated to the Hong Kong public tranche and 90% to international placement. There is no over-allotment option. A board lot consists of 50 shares, and the entry cost at the maximum offer price works out to approximately HK$2,552.99 per lot — a relatively low threshold that puts the capital required for retail participation in the lower to mid-range of the new-issue market. Joint sponsors are GF Securities (Hong Kong) and ABC International.

The company positions itself as a major supplier of traditional Chinese medicine decoction pieces in China. According to Frost & Sullivan data cited in the prospectus, Neautus ranked second in the Chinese market by 2025 revenue from these products, with a market share of approximately 0.4%. The top five players combined held just 2.7%. That level of fragmentation means no single participant can rely on scale alone to build a meaningful competitive moat. The company's product range covers more than 770 categories and 4,900 specifications, with hospitals, medical institutions and pharmacy chains forming its core customer base.

Revenue for 2023, 2024 and 2025 stood at RMB1.146 billion, RMB1.249 billion and RMB1.335 billion respectively, with the year-on-year growth rate gradually slowing. Net profit over the same period was RMB104 million, RMB89 million and RMB106 million. In the first four months of 2026, revenue reached RMB432 million, up about 12.9% from RMB383 million in the comparable period of 2025. Gross profit increased from RMB72.2 million to RMB94.2 million, and gross margin improved from 18.9% to 21.8%. The prospectus does not elaborate on the specific factors behind the simultaneous profit volatility and margin expansion.

The listing document confirms that no cornerstone investors were secured for this offering, so all shares will be priced through the public market and subscription response will directly influence final pricing and allocation. According to data compiled by brokers and reported by Sing Tao Daily and now E-news, margin subscriptions on day one reached approximately HK$96.84 million. Against a public tranche target of HK$32.95 million, that translates to an oversubscription of about 1.94 times, pointing to cautious market sentiment. Final pricing and allotment results will be announced on 10 November.

Source: IPO Tracker The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.